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Human chorionic gonadotropin (hCG) is
a glycoprotein hormone consisting of two
dissimilar subunits, α and ß. HCG is pro-
duced by the placental trophoblasts and
its function is to maintain pregnancy. The
free subunits have no known biological
function. The ß subunit (hCGß) is com-
monly produced at low concentrations by
many cultured cells and malignant tumors
of various origin, in which it frequently is
a sign of aggressive disease. Clinically
hCGß is a valuable marker for monitor-
ing of trophoblastic tumors and testicular
carcinoma.
Reverse transcription-polymerase chain
reaction (RT-PCR) of hCGß mRNA was
used in this study to detect cells expressing
hCGß in blood and urine. HCGß expres-
sion was induced by culture of peripheral
blood cells, but no expression was observed
in unstimulated blood cells. HCGß mRNA
expression was detected in the urinary cells
of approximately 50% of patients with blad-
der cancer but not in healthy controls. The
expression was strongly associated with his-
tologically proven carcinoma but not with
stage and grade of the tumor. Immunohis-
tochemical expression of hCGß protein was
found in tumor tissue from one third of the
cancer patients but equally often in benign
epithelium. Current or previous instillation
therapies did not affect the detection of
hCGß mRNA in urinary cells or tissue ex-
pression detected by immunohistochemis-
try. The urine concentrations of the hCGß
core fragment, a degradation product of
hCGß, were higher in patients with hCGß
mRNA in urine and the urine to serum ra-
tio of hCGß was strongly associated with
both stage and grade of the disease, and also
with immunohistochemical detection of
hCGß.
Our findings show that hCGß expression
is not cancer specific, but it may occur in
benign conditions. The ratio of urine to se-
rum hCGß demonstrates that local produc-
tion of hCGß by the tumor correlates with
stage and grade of the disease, supporting
previous data on the association of hCGß
with advanced disease.
To study whether hCGß has prognostic
significance in renal cell carcinoma (RCC)
preoperative serum samples from patients
with RCC were analyzed. The serum con-
centrations were elevated in 23% of the pa-
tients and hCGß was a prognostic marker
independent of stage and grade of the tu-
mor. Our results suggest that hCGß expres-
sion characterizes a potentially aggressive
subgroup of tumors.
Kristina Hotakainen
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Introduction
Bladder and kidney cancer are two fairly
common malignancies, for which few reli-
able tumor markers are available. Markers
that could be used for diagnosis, monitor-
ing and evaluation of prognosis would be
of clinical value. The free ß subunit of hu-
man chorionic gonadotropin (hCG) in se-
rum has proved to be useful as a prognostic
marker especially for ovarian and various
gastrointestinal cancers.
This study was undertaken to investi-
gate whether hCGß expression could be
used as a marker for bladder and kidney
cancer. We studied whether hCGß mRNA
in urinary cells can be used to detect blad-
der cancer and if this finding correlates
with serum and urine concentrations of
hCGß and immunohistochemical staining
of hCGß in tumor tissue, as well as with
stage and grade of the tumor. The clinical
course of renal cell carcinoma (RCC) is
unpredictable, and no specific serum
markers are available. We therefore stud-
ied whether hCGß in serum of RCC pa-
tients is of diagnostic and prognostic value
for this disease.
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1. CHORIONIC GONADOTROPIN
AND ITS SUBUNITS
1.1 Biochemistry and biology
Human chorionic gonadotropin (hCG) is a
member of the glycoprotein hormone fam-
ily, which also comprises luteinizing hor-
mone (LH), follicle stimulating hormone
(FSH) and thyroid stimulating hormone
(TSH). These hormones are heterodimers
consisting of an α and a ß subunit. The free
subunits are devoid of hormonal activity
(Catt et al., 1973; Rayford et al., 1972). The
α subunit common to hCG, LH, FSH and
TSH contains 92 amino acids. The ß chains
are hormone specific and determine the bio-
logical activity. The ß subunit of hCG
(hCGß) contains 145 amino acids includ-
ing a 24 amino acid C-terminal extension
lacking in LHß. The homology between the
ß chains of hCG and LH is about 80% and
hCG and LH exert their action through the
same receptor (McFarland et al., 1989). The
molecular weights of hCG, hCGß and
hCGα are 36700, 22200 and 14500 Da, re-
spectively (Birken, 1984). HCGα is encoded
by a single gene on chromosome 12q21.1-
23 and hCGß by a cluster of six nonallelic
genes on chromosome 19q13.3 (Boothby et
al., 1981; Talmadge et al., 1984b).
1.2 Biological function
HCG is produced at high concentrations by
placental syncytiotrophoblasts. HCG main-
tains pregnancy by stimulating progester-
one production in the corpus luteum dur-
ing the first trimester (Yoshimi et al., 1969).
It also stimulates testosterone production
by fetal testes (Huhtaniemi et al., 1977).
Receptors for hCG/LH have been identified
in the nonpregnant uterus (Reshef et al.,
1990), prostate (Dirnhofer et al., 1998a) and
several extragonadal sites such as leukocytes
(Lin et al., 1995), thyroid (Frazier et al.,
1990) and epidermal structures (Venencie
et al., 1999).
1.3 HCG in serum and urine of healthy
subjects
Low concentrations of hCG are produced
by the pituitary giving rise to measurable
plasma levels. The serum concentrations are
correlated with those of LH and thus they
increase with age both in men and in women
(Stenman et al., 1987). Age- and gender
specific reference values in serum and urine
are given in table 1. In healthy nonpreg-
nant subjects the α subunit originates
mostly from the pituitary, but some pitu-
itary adenomas may secrete hCGß (Gil-del-
Alamo et al., 1995). HCGα can be detected
at levels up to 3 ng/l in the serum of most
healthy individuals (87%), patients with
benign diseases (93%), and various nontro-
phoblastic cancers (96%) (Marcillac et al.,
1992).
HCG and hCGß are excreted into urine
and the concentrations are comparable to
those in plasma. The concentrations of
hCGα in urine are 3-5-fold those in serum
(Landy et al., 1990; Iles & Chard, 1991).
Much of hCG and hCGß is degraded dur-
ing excretion and a variable part of the hCG
immunoreactivity in urine consists of a frag-
ment of hCGß called the core fragment
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(hCGßcf) (Papapetrou & Nicopoulou,
1986).
1.4 HCG in malignant disease
The expression of hCG in serum of cancer
patients is a classic example of ectopic hor-
mone production (Braunstein et al., 1973;
Weintraub & Rosen, 1973; Hattori et al.,
1978). Most cultured human fetal and can-
cer cells express hCGß, hCGα as well as in-
tact hCG (Acevedo et al., 1992). However,
detectable serum concentrations of hCGα
and hCG occur in normal individuals also,
whereas elevated levels of hCGß are fre-
quently associated with malignant tumors
(Marcillac et al., 1992; Alfthan et al.,
1992b). Most nontrophoblastic tumors pro-
duce hCGß exclusively, but isolated produc-
tion of hCGα has recently been described
in an immunohistochemical study of neu-
roendocrine lung carcinoma (Dirnhofer et
al., 2000). Carcinoid tumors of the pancreas
frequently express hCGα (70%) in the ab-
sence of hCGß (Öberg & Wide, 1981), and
immunocytochemical staining of hCGα can
be observed equally often in endocrine pan-
creatic tumors (Heitz et al., 1983). Over-
expression of hCGα in relation to hCGß at
the mRNA level has been shown in breast
cancer tissue, and these transcripts are also
translated into hCGß protein (Giovangrandi
et al., 2001). In addition, some gastrointes-
tinal and gynecological cancers may produce
hCGα exclusively (Huang et al., 1989).
Various minor molecular forms of hCG may
occur in the urine of cancer patients, e.g.,
nicked and hyperglycosylated forms, and
variants lacking the C-terminal extension
of hCGß (Cole et al., 2001).
1.5 Clinical determinations
1.5.1 Normal pregnancy
During pregnancy the concentrations of
hCG become detectable 5-7 days after con-
ception and increase exponentially with a
doubling time of about 1.5 days. Peak val-
ues are reached at 7-10 weeks of pregnancy.
After this the levels decrease slowly until
the 15th week, after which there is a small
gradual increase towards term. The concen-
trations of hCGß are about 0.5-1% of the
total hCG concentration, whereas those of
hCGα are less than 10% during the first
trimester increasing to 30-60% at term.
Low concentrations of hCGßcf occur in
pregnancy serum (<1% of the total hCG
concentration) (Alfthan & Stenman, 1990;
Kardana & Cole, 1990). In urine hCGßcf is
the major form of hCG immunoreactivity
and the concentration is about 4000-fold
that in serum (Wehmann et al., 1990). Preg-
nancy can be diagnosed by detecting el-
evated hCG concentrations in urine or se-
rum by the time of the first missed men-
strual period.
1.5.2 Ectopic pregnancy
Ectopic pregnancy can be diagnosed when
no intrauterine gestational sac is seen by
ultrasonography and the hCG level is greater
than 1000 IU/l (Cacciatore et al., 1995). The
hCG concentration at day 44 after the last
menstrual period can also be used to pre-
dict spontaneous resolution of an ectopic
pregnancy (Korhonen et al., 1994).
hCG
hCGβ
hCGβcf
hCGα
8.6
1.6
1.1
301
15.5
2.0
1.1
602
2.1
1.9
1.1
6.1
2.1
1.1
WomenSerum
≥50<50 ≥50<50
Men
Upper reference limit (pmol/l)
Table 1. Reference values for hCG, hCGβ, hCGβcf
and hCGα in serum and urine of women and men
(Alfthan et al., 1992a).
Age (years)
1In subjects with a serum concentration of FSH < 20;
2FSH ≥ 20 (Alfthan et al., unpublished data).
hCG
hCGβ
hCGβcf
Urine
8.8
1.7
8.1
11.5
4.3
9.5
2.9
1.3
6.7
8.4
3.6
8.5
11
1.5.3 Maternal screening for Down’s syndrome
HCG and hCGß in serum or urine can be
used in the diagnosis of various pregnancy-
related disorders and chromosomal abnor-
malities of the fetus (Cuckle et al., 1999).
Serum concentrations of hCG or hCGß in
combination with other markers are used
in screening of fetal trisomy 21. The risk
increases with increasing concentration of
hCG and hCGß and decreasing levels of al-
pha fetoprotein (AFP) (Phillips et al., 1992).
1.5.4 Trophoblastic disease
Elevated levels of both hCG and hCGß are
encountered in virtually all cases of molar
disease and choriocarcinoma. The propor-
tion of hCGß to hCG may be used to dif-
ferentiate between these. In benign disease
the proportion is below 5% (on a molar
basis) and in choriocarcinoma the propor-
tion exceeds 6% (Ozturk et al., 1988;
Stenman et al., 1995; Vartiainen et al.,
1998).
1.5.5 Testicular cancer
Germ cell tumors of the testis represent
more than 95% of all testicular cancers.
These are classified as seminomas (30-40%)
and nonseminomatous germ cell tumors of
the testis. HCG and hCGß are important
markers for both tumor types. HCG is used
both as a prognostic factor, for monitoring
of the response to therapy and during fol-
low up of the disease. Seminoma patients
have elevated serum levels of hCG in 10-
30% of the cases. Of all hCG-producing
seminomas 30- 40% have elevated serum
levels of both hCG and hCGß, 25% of hCG
only and 35% of only hCGß (Koshida et al.,
1996; Weissbach et al., 1997). Elevated se-
rum concentrations of hCG are associated
with adverse prognosis (Bosl et al., 1981;
Droz et al., 1988; von Eyben et al., 2001),
and the risk increases with increasing con-
centrations (Vogelzang, 1987). HCGß
mRNA expression has been demonstrated
by reverse transcription-polymerase chain
reaction (RT-PCR) in peripheral blood of
patients with germ cell tumors, and more
frequently in those with elevated serum con-
centrations of hCGß. However, the clinical
significance of this phenomenon is unclear
(Hautkappe et al., 2000).
1.6 The beta subunit of chorionic
gonadotropin
1.6.1 Genes, mRNAs and proteins
HCGß is encoded by a cluster of genes num-
bered ß1 to ß9 on chromosome 19q13.3.
The homology between the hCGß and LHß
genes is 94% (Talmadge et al., 1983;
Talmadge et al., 1984b), and the hCGß gene
has probably arisen through duplication of
an ancestral LHß gene (Boorstein et al.,
1982). The gene cluster comprises six non-
allelic hCGß genes and the gene encoding
LHß. ß1 and ß2 are considered pseudogenes
that are not expressed, while ß7 and ß9 are
alleles to ß6 and ß3, respectively (Policastro
et al., 1983; Policastro et al., 1986). How-
ever, it is possible that ß1 and ß2 can pro-
duce alternatively spliced transcripts giv-
ing rise to a hypothetical protein 132 amino
acids in length (Dirnhofer et al., 1996).
Genes ß6 and ß7 (type I genes) encode a
protein with alanine at position 117 while
genes ß3/9, ß5 and ß8 (type II genes) en-
code a protein containing aspartic acid at
this position. The transcriptional activity
varies among the various hCGß genes, and
also among individuals. In the placenta,
gene 5 is the one with the strongest expres-
sion, followed by genes 3 and 8 with gene
7 accounting for less than 2% of the total
expression (Bo & Boime, 1992; Miller-
Lindholm et al., 1997). A similar pattern is
common also in nontrophoblastic tissues;
Giovangrandi and coworkers recently
showed that the increased hCGß mRNA
expression observed in breast cancer tissue
is mainly due to overexpression of genes 5,
Review of the Literature
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8 and 3 (Giovangrandi et al., 2001). Tran-
scripts of these genes have been demon-
strated in testicular tumors also
(Madersbacher et al., 1994). The differen-
tial expression results from differences in
the promoter regions of the genes (Otani et
al., 1988). The mRNA of hCGß contains
879bp (Talmadge et al., 1984a).
HCGß is 145 amino acids in length. It
contains six carbohydrate chains and the
molecular weight is 22200 Da. The three-
dimensional structure of hCGß resembles
that of the so-called cysteine knot growth
factors, e.g. nerve growth factor, platelet
derived growth factor (PDGFß), transform-
ing growth factor (TGFß) and vascular
endothelial growth factor (VEGF) (Lapthorn
et al., 1994; Muller et al., 1997). These
growth factors bind to their receptors both
as homo- and heterodimers. HCGß has been
shown to exist as a homodimer (Butler et
al., 1999), and thus it may also bind to a
hypothetical receptor as a homodimer.
However, no receptor for hCGß or hCGßß
has been identified.
1.6.2 HCGß expression in tissues and body
fluids
HCGß occurs in serum of men and non-
pregnant females at levels 5 to 10-fold lower
than those of hCG. The serum levels are not
related to those of hCG or LH and they are
not age-dependent (Alfthan et al., 1992a).
Expression of hCGß mRNA has been dem-
onstrated in several tissues, i.e., bladder,
adrenal, colon, testis, breast, thyroid and
uterus, in which the expression is about
10,000-fold lower than in the placenta
(Bellet et al., 1997). Expression of hCGß in
normal nontrophoblastic tissues is mostly
associated with type I gene expression but
testicular tissue also expresses type II genes.
The placenta, trophoblastic and other ma-
lignant tumors express predominantly type
II genes (Bellet et al., 1997).
Moderately elevated serum concentra-
tions of hCGß protein occur in 30-70% of
most nontrophoblastic cancers (Alfthan et
al., 1992b; Marcillac et al., 1992) and it has
been suggested that activation of the hCGß/
LHß gene cluster is characteristic of malig-
nant transformation (Acevedo et al., 1995;
Bellet et al., 1997; Krichevsky et al., 1995).
Membrane-bound hCGß has been found to
be characteristic of a metastatic phenotype
of cancer cells (Acevedo & Hartsock, 1996).
HCGß stimulates the growth of certain can-
cer cell lines in culture, and it is proposed
to act as an autocrine or paracrine growth
factor (Gillott et al., 1996). The growth
promoting effect of hCGß may partly re-
sult from inhibition of apoptosis (Butler et
al., 2000).
1.6.3 HCGß expression in peripheral blood
cells
Low level expression of several genes
thought to be specific for other organs can
be observed in peripheral blood cells (Azad
et al., 1993; Lintula & Stenman, 1997). Leu-
kocytes have the potential of producing sev-
eral peptide hormones (Blalock et al., 1985;
Harbour-McMenamin et al., 1986; Smith
et al., 1985), and receptors for LH/hCG have
been identified on leukocytes (Lin et al.,
1995). Cultured cells from leukemias and
lymphomas express membrane-bound hCG
and its subunits (Acevedo et al., 1992).
HCG immunoreactivity has been induced
in lymphocytes by mixed lymphocyte cul-
tures, but not by other mitogenic stimuli
(Harbour-McMenamin et al., 1986). Dur-
ing pregnancy, peripheral blood mono-
nuclear cells are capable of secreting hCG
(Alexander et al., 1998).
1.6.4 HCGß in malignant disease
HCGß expression can be detected by im-
munohistochemistry in 20-52% of colorec-
tal carcinomas and the expression is associ-
ated with poorly differentiated and ad-
vanced tumors (Kido et al., 1996;
Yamaguchi et al., 1989; Campo et al., 1987).
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In one study, only serum concentrations
were found significantly correlated with the
clinical outcome (Webb et al., 1995). The
prognostic significance has later been con-
firmed both for serum concentrations and
immunohistochemical detection of hCGß
(Lundin et al., 2001; Carpelan-Holmström
et al., 1996).
HCG immunoreactivity has been de-
scribed in squamous cell carcinoma cell lines
(Cole et al., 1981; Cowley et al., 1985). In
immunohistological studies of the esopha-
gus (Burg-Kurland et al., 1986; Trias et al.,
1991), oral cavity (Bhalang et al., 1999) and
uterine cervix, hCG expression has been
associated with poorly differentiated tu-
mors. Preoperatively elevated serum levels
of hCGß predict shorter recurrence free sur-
vival of patients with squamous cell carci-
nomas of the oral cavity and oropharynx
(Hedström et al., 1999).
Serum levels of hCGß are rarely elevated
in vulvar carcinomas, but progressive dis-
ease is associated with rising levels (de
Bruijn et al., 1997). The concentrations of
hCGß in serum have a prognostic signifi-
cance in ovarian carcinoma (Ind et al., 1997;
Vartiainen et al., 2001). Urinary hCGßcf has
been used as a marker of gynecological can-
cers (Cole et al., 1988; Wang et al., 1988).
HCGß mRNA is expressed in several
pancreatic cancer cell lines, and also in tis-
sue samples from metastatic pancreatic can-
cer (Bilchik et al., 2000). Elevated serum
concentrations of hCGß have been described
in 40-70% of patients with pancreatic  and
biliary cancer. In most of these, urinay con-
centrations of hCGßcf are also elevated
(Alfthan et al., 1992b; Motoo et al., 1996).
Elevated hCGß in serum has been reported
to correlate with adverse outcome in the
cancer patients (Syrigos et al., 1998).
RT-PCR of hCGß mRNA has been used
to detect circulating melanoma cells (Hoon
et al., 1995) and melanoma metastases in
lymph nodes (Doi et al., 1996). Recently,
Taback and coworkers showed that detec-
tion of hCGß mRNA expression in circu-
lating cells from patients with breast can-
cer is significantly associated with tumor
size (Taback et al., 2001). Hu and cowork-
ers found an association between stage and
detection of hCGß mRNA in blood of breast
cancer patients (Hu & Chow, 2000). In both
studies the combination of hCGß with an-
other marker significantly improved the
correlation (Hu & Chow, 2001). However,
hCGß mRNA expression also occurs in be-
nign breast tumors (Reimer et al., 2000).
1.6.5 HCGß expression in bladder cancer
Approximately 70% of both benign and
malignant urothelial cells in culture express
hCG-like material, almost entirely consist-
ing of hCGß (Iles et al., 1987; Iles & Chard,
1989; Iles et al., 1990b). Elevated levels of
hCGß, and rarely intact hCG, can be de-
tected in serum and urine from patients
with transitional cell carcinomas (TCC) of
the bladder. Both serum and urine concen-
trations of hCGß are elevated in up to 70%
of the patients with metastatic disease (Iles
et al., 1989; Iles et al., 1996) but in less
than 10% of patients with local tumors (Iles
et al., 1989; McLoughlin et al., 1991; Smith
et al., 1994). The degradation of hCGß may
lead to increased concentrations of hCGßcf
in urine, but it is possible that some tu-
mors synthesize and secrete hCGßcf into the
urine (Iles et al., 1990a; Dirnhofer et al.,
1998b).
Approximately 30% of TCCs express
hCGß and this expression seems to charac-
terize an aggressive subgroup of tumors.
Elevated serum and urine concentrations of
hCGß in advanced disease have been shown
to predict the development of metastasis and
relapses as well as increased mortality (Iles
et al., 1996; Marcillac et al., 1993). HCGß
expression detected by immunohistochem-
istry is associated with a poor response to
radiotherapy (Martin et al., 1989; Jenkins
et al., 1990; Moutzouris et al., 1993) and
the serum concentrations of hCGß corre-
late with the response to chemotherapy
Review of the Literature
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(Dexeus et al., 1986; Mora, J. et al., 1996;
Cook et al., 2000).
1.6.6 HCGß expression in renal cell
carcinoma (RCC)
Many earlier studies have failed to show
any hCG immunoreactivity in serum or
tumor tissue of patients with RCC (Sufrin
et al., 1977; Kuida et al., 1988;
Dunzendorfer et al., 1981). However, hCG
immunoreactivity has been detected by ra-
dioimmunoassay in urinary concentrates
from patients with advanced or poorly dif-
ferentiated tumors (Fukutani et al., 1983),
but the number of patients in the study was
very small. Elevated serum concentrations
of hCGß have been reported to occur in 10%
of the patients, and the levels correlate with
the clinical course (Dexeus et al., 1991).
 2. BLADDER CANCER
2.1 Epidemiology
Bladder cancer is one of the most common
malignancies among men in the Western
world (Parkin et al., 1999). Bladder cancer
accounts for approximately 4% of all new
cancer cases in Finland, being the 3rd most
common malignancy in men and 16th in
women. The age-adjusted incidence rate has
increased from 10 to 19 cases per 100 000
inhabitants during the past 30 years (Finn-
ish Cancer Registry, 2000), and it is still
expected to grow. Bladder cancer is a dis-
ease of the aged; mean age at presentation
in 1985-1994 was 69 years for males and
72 for females (Dickman et al., 1999).
2.2 Risk factors
Smoking increases the risk of bladder can-
cer (Sorahan et al., 1994), and more so in
women than in men (Castelao et al., 2001).
Occupational  and other exposure to aro-
matic amines is an established risk factor
(Boffetta et al., 1997; Steineck et al., 1990)
and certain alkylating agents such as cyclo-
phosphamide have also been reported to
induce bladder cancer (Durkee & Benson,
1980). Chronic inflammation and regenera-
tion processes caused by schistosomal in-
fection of the bladder induce squamous
metaplasia which may lead to development
of cancer (Johansson & Cohen, 1997).
2.3 Histology
TCC is by far the most common histologi-
cal type of bladder cancer, accounting for
90-95% of the cases in industrialized coun-
tries (Dickman et al., 1999). The remain-
der are squamous cell carcinomas (3-6%),
adenocarcinomas (1-3%), or undifferenti-
ated carcinomas (1%) (Mostofi FK, 1973).
Squamous cell carcinomas are frequently
associated with schistosomal infection, and
in endemic areas for schistosomiasis 75%
of bladder cancers are squamous cell carci-
nomas, 6% adenocarcinomas and the re-
mainder transitional (Johansson & Cohen,
1997).
2.4 Symptoms and signs
The most frequently encountered sign of
bladder cancer is painless and intermittent
hematuria. This can be microscopic, but in
75% of the cases an episode of macrosopic
hematuria can be verified (Varkarakis et al.,
1974). Lower abdominal pain, frequency,
urgency and dysuria occur in approximately
one third of the patients with invasive dis-
ease (Utz et al., 1980).
2.5 Diagnostic procedures
Urinary cytology is the primary tool for
detection and follow up of bladder cancer
(Lewis et al., 1976; Papanicolaou &
Marshall, 1945). It is sensitive and specific
in high-grade or invasive tumors, but less
so in superficial and low-grade cancers
(Esposti et al., 1978; Rubben et al., 1979;
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Badalament et al., 1987b; Hudson & Herr,
1995; Koss et al., 1985).
Cystoscopy is the gold standard for de-
tecting bladder cancer. By diagnostic cys-
toscopy the extent and nature of the tumor
can be evaluated in addition to the state of
the urethral and bladder mucosae. Accurate
staging requires biopsies including the
muscular layer of the bladder wall (See &
Fuller, 1992). Concomitant upper urinary
tract disorders are excluded by intravenous
urography (Hatch & Barry, 1986). Larger
tumor masses in the bladder can be detected
by transabdominal sonography. Possible
muscle invasion can be evaluated by intra-
vesical sonography. Computerized tomog-
raphy and magnetic resonance imaging are
used as supplements to clinical staging and
evaluating metastatic spread of muscle-in-
vasive tumors (Barentsz et al., 1996; See &
Fuller, 1992).
2.6 Staging and grading
Stage classification of bladder cancer is per-
formed according to the TNM classification
of bladder cancer (Sobin & Wittekind,
1997). However, a previous classification of
1978 (UICC, 1978) is used in many stud-
ies to make comparison with earlier reports
easier (Table 2). The tumors are graded into
three grades according to the World Health
Organization classification (Mostofi, 1973).
More recently, new grading systems for pap-
illary carcinomas have been suggested, in
which the previous grades two and three
are classified low and high grade, respec-
tively. The previous grade 1 carcinoma is
classified as a papillary tumor of low ma-
lignant potential (Table 3) (Epstein et al.,
1998). Carcinoma in situ (Tis) is a distinct
category of flat intraepithelial malignant
proliferation (UICC, 1978). This carcinoma
is an aggressive and potentially invasive
high grade tumor (Wolf & Hojgaard, 1983).
2.7 Treatment and prognosis
Superficial tumors (Ta and Tis) are treated
by transurethral resection alone or in com-
bination with intravesical chemo- or immu-
notherapy (Soloway, 1983; Soloway &
Perito, 1992). Invasive and highly recurrent
tumors are managed by cystectomy together
with adjuvant treatments such as systemic
chemotherapy and radiotherapy (Soloway,
1990). After initial therapy, all patients en-
ter a follow up scheme consisting of uri-
nary cytology and cystoscopy every 3-4
months during the first two years, and later
TX
T0
Tis
Ta
T1
T2
T3a
T3b
T4a
T4b
N
M
Primary tumor can not be assessed
No evidence of primary tumor
Carcinoma in situ (flat tumor)
Papillary non-invasive carcinoma
Tumor infiltrating the lamina propria
Tumor infiltrating the superficial muscle
Tumor infiltrating the deep muscle
Tumor infiltrating through the bladder wall
into the perivesical fat
Carcinoma involving the prostate, uterus
or vagina
Carcinoma invading the abdominal or
pelvic wall
Lymph node involvement
(N0=without, N1-4=with)
Distant metastasis (M0=without, M1=with)
Table 2. TNM stage classification of bladder cancer.
Tis
Ta
T1
T2
T2a
T2b
T3
T3a
T3b
T4
T4a
T4b
N
M
Carcinoma in situ (flat tumor)
Papillary non-invasive carcinoma
Tumor infiltrating the lamina propria
Tumor infiltrating the muscle
Tumor infiltrating the superficial muscle
Tumor infiltrating the deep muscle
Tumor infiltrating perivesical tissues
Microscopically
Macroscopically
Tumor infiltrating perivesical organs
Carcinoma involving the prostate, uterus
or vagina
Carcinoma invading the abdominal or pelvic wall
Lymph node involvement
(N0=without, N1-3=with)
Distant metastasis (M0=without, M1=with)
5th edition (Sobin & Wittekind, 1997) 3rd edition (UICC, 1978)
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every 6-12 months (Nurmi & Rintala,
2002).
Most bladder cancers are superficial at
diagnosis, but approximately 75% recur,
and progression to more advanced stage
occurs in up to 40% by ten years (Heney et
al., 1983; Herr, 1997; Herr et al., 1995;
Pagano et al., 1987). In Tis the long-term
risk of progression to invasiveness or me-
tastases is even higher, 60-70% (Cookson
et al., 1997; Herr, 2000). High grade and
tumor multiplicity are associated with a
higher recurrence rate (Heney et al., 1983).
However, 27% of patients with papillary
tumors of “low malignant potential” will
experience tumor recurrence and progres-
sion of grade occurs in 75% (Cheng et al.,
1999). Stage is the most accurate prognos-
tic indicator; the 5-year survival rate de-
clines with increasing stage, being only 0-
21% in stage T4 and as high as 80-94% in
stage Ta (Malmström et al., 1987; Torti &
Lum, 1984). Age is also consistently asso-
ciated with survival, with a more favourable
outlook in the younger age groups
(Dickman et al., 1999).
2.8 Markers of bladder cancer
The high recurrence rate and the risk of
progression necessitates a close surveillance
of bladder cancer. Furthermore, a signifi-
cant number of recurrences occur more than
five years after primary diagnosis, which
justifies a lifelong follow up (Cheng et al.,
1999; Cookson et al., 1997; Leblanc et al.,
1999). An optimal marker would facilitate
noninvasive diagnosis and follow up of blad-
der carcinoma. The test should be economic,
well standardized and reproducible, easy to
perform and most importantly, sensitive and
specific. Furthermore, the ability to esti-
mate stage and grade and to characterize
the malignant potential and prognosis
would be valuable.
Urinary cytology is the reference stan-
dard to which potential new tests are com-
pared. The sensitivity of cytology ranges
from 70-100% in Tis and other high-grade
carcinomas, with a specificity of more than
95% (Badalament et al., 1987a; Bastacky et
al., 1999). However, in low-grade superfi-
cial tumors the sensitivity is at best no more
than 40%. Urinary calculi, infection, instil-
lation therapies and other treatments may
cause cellular atypia leading to falsely posi-
tive cytology, but specificity is still better
than 80% regardless of stage and grade
(Murphy et al., 1984).
A multitude of biomarkers for bladder
cancer is being studied. These can roughly
be classified into two categories; markers
for screening and diagnosis of bladder can-
cer (Table 4) and potentially prognostic
markers (Table 5). Some tests are being
clinically used as complements to urinary
cytology and cystoscopy and others are un-
der clinical evaluation. The best new mark-
ers give higher sensitivity than urinary cy-
tology, but specificity is generally lower
(Brown, 2000; Burchardt et al., 2000).
However, the cytologic methods, to which
new tests are being compared, are not well
standardized. This makes evaluation of their
true performance difficult, and up to date
no noninvasive test is sensitive and specific
enough to replace cytology and cystoscopy.
However, the intervals between follow up
cystoscopies can be increased and the de-
tection of relapse can be improved by using
the new markers.
2.8.1 Markers for screening and
diagnosis
Assays for nuclear matrix protein 22
Papilloma
LMP
Low grade
High grade
Papilloma
Grade 1
Grade 2
Grade 3
Papilloma
Grade 1
Grade 2
Grade 3
1Mostofi FK, 1973; 2Epstein et al., 1998; 3Cheng & Bostwick, 2000.
Table 3. Histologic grading of papillary urothelial
carcinoma.
WHO/ISUP
1998 2
Current
proposal3
WHO
19731
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(NMP22) and human complement factor
H-related protein (BTA stat and TRAK
tests) are the most widely used new mark-
ers for diagnosis and follow up of bladder
cancer. NMP22 is a urothelial cancer asso-
ciated nuclear matrix protein (Soloway et al.,
1996). High NMP22 concentrations in
urine are associated with active disease
(Carpinito et al., 1996). The sensitivity is
at least twice that of cytology (Sozen et al.,
1999), but specifity (61-85%) (Serretta et
al., 1998; Zippe et al., 1999) is compro-
mized by benign urologic disorders
(Miyanaga et al., 1997) and therapies (Öge
et al., 2000). This limitation also applies to
the various BTA-tests (Pode et al., 1999;
Sanchez-Carbayo et al., 1999). Furthermore,
elevated NMP22 concentrations in urine
have also been observed in patients with
renal cell carcinoma (Huang et al., 2000).
Previous (Bacillus Calmette-Guérin, BCG)
and current (any type) instillation treat-
ments lower the specificity of the BTA stat
significantly limiting its use in the follow
up of bladder cancer (Raitanen et al., 2001).
Part of the telomeres in somatic cells are
degraded with every replication round
(Harley et al., 1990). Telomerase is a ribo-
nucleoprotein enzyme with reverse tran-
scriptase activity, which maintains the te-
lomeres in replicating germ cells thus mak-
ing repeated rounds of replication possible
without loss of parent DNA sequences
(Blackburn, 1991). Telomerase activity is
low or absent in normal cells but it is often
detected in voided urine of bladder cancer
patients regardless of grade (Kavaler et al.,
1998). Telomerase tests have been reported
to outperform both NMP22 and BTA as-
says as well as conventional cytology both
in sensitivity and specificity (Ramakumar
et al., 1999). However, the method is costly
and laborious, making it less feasible for
routine clinical use (Ross & Cohen, 2000).
Increased urinary levels of fibrinogen
degradation products (FDP) occur in pa-
tients with bladder cancer, and these can
be detected by an immunoassay. Initially,
the method was assigned a sensitivity of
of 68-100% and a specificity of 75-96%
(Johnston et al., 1997; Schmetter et al.,
1997) in detecting bladder neoplasia, but
later a sensitivity of merely 48% was re-
ported (Ramakumar et al., 1999).
2.8.2 Prognostic markers
An increasing list of protein and genetic
alterations is under research as prognostic
markers of bladder cancer (Table 5). Of
these, assays for microsatellite instability,
VEGF and some tumor-associated antigens
can be performed on urinary cytology or
bladder washing specimens. This also ap-
plies to flow cytometry (FCM), by which
DNA-ploidy and S-phase fraction (SPF, frac-
tion of cells in the population being in the
DNA-synthesis phase) are measured. Aneu-
ploid cell populations and those with a high
SPF are typical of high grade and stage tu-
mors (Klein et al., 1982; Koss et al., 1989;
Schapers et al., 1993). The reported sensi-
tivity of DNA-ploidy analyzed by FCM for
detection of urothelial neoplasia ranges from
34% to 88% (Badalament et al., 1987a;
Gregoire et al., 1997; Murphy et al., 1986)
with a specificity exceeding 80% (Bakhos
et al., 2000; Gregoire et al., 1997). How-
ever, the number of cells needed can rarely
be obtained from voided urine, but a blad-
der washing sample is required. The test is
compromised by large amounts of non-ma-
lignant cells in the sample. In addition, only
gross genetic alterations leading to changes
in DNA-ploidy can be detected by FCM.
Thus, diploid tumors and those with bal-
BTA (BTA TRAK; BTAstat)
NMP22
FDP
Telomerase
Cell surface antigens (M344, 19A211, LDQ10)
Hyaluronic acid/ hyaluronidase
Cytokeratins
Table 4. Markers for screening and diagnosis
of bladder cancer.
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anced translocations pass undetected, that
is most of grade 1, stage 1 tumors and up
to half of grade 2 lesions (Bucci et al., 1995;
Kawamura et al., 2000; Liedl, 1995;
Tribukait & Esposti, 1978). Furthermore,
despite a higher overall sensitivity than for
cytology (Badalament et al., 1987c; Giella
et al., 1992; Song et al., 1995) FCM fails to
detect most in situ carcinomas which are
detected by urinary cytology. In summary,
analyses for DNA-ploidy can be useful in
differentiating benign atypia associated
with instillation therapies from recurrent
neoplasia (Bakhos et al., 2000), but the
prognostic utility is limited (Bittard et al.,
1996; Tetu et al., 1996) and the method is
too insensitive for screening (Gourlay et al.,
1995).
Combined with conventional cytology,
DNA-ploidy measured by static image
analysis (IA) can detect up to 85% of recur-
rent tumors (Cajulis et al., 1995; de la Roza
et al., 1996; Mora, L.B. et al., 1996;
Richman et al., 1998). Laser scanning
cytometry (LSCM) combines the advantages
of FCM and image analysis and measures
the DNA-content in individual cells. Small
cell populations with aberrant DNA-con-
tent can be detected by these newer meth-
ods, and thus they may also be used for
voided urine (Parry & Hemstreet, 1988;
Wojcik et al., 1998). Aberrant cellular
DNA-content can also be visualized by fluo-
rescence in situ hybridization (FISH). This
method has been reported to be capable of
differentiating between Ta and T1 tumors
and also of predicting response to immu-
notherapy (Pycha et al., 1997; Sauter et al.,
1997). However, the sensitivity is highly
dependent on the number of centromeric
probes used, and due to the heterogenous
nature of bladder cancer multiple probes are
needed (Sauter et al., 1997). The possibil-
ity to also detect superficial tumors and to
obtain prognostic information makes the
method promising for the follow up of blad-
der cancer patients. Microsatellite analyses
can detect tumor-associated alterations in
repetitive DNA sequences of the human
genome (microsatellites). In bladder cancer,
microsatellite instability and loss of het-
erozygosity is frequently observed in char-
acteristic chromosomes. The analysis can be
performed on voided urine with a high sen-
sitivity (74-95%) in detecting recurrent
tumors (Mao et al., 1996; Steiner et al.,
1997; van Rhijn et al., 2001) even months
before these are detected by cystoscopy. In
addition, the test can also be used on frozen
urine samples (Linn et al., 1997). However,
microsatellite instability and loss of het-
erozygosity in urine are frequently found
in benign urological disorders such as be-
nign prostatic hyperplasia and cystitis also
(Christensen et al., 2000). Thus the high
specificity initially reported (Mao et al.,
1996; Mourah et al., 1998; Steiner et al.,
1997; van Rhijn et al., 2001) may be over-
estimated.
The expression of many growth factors
is altered in bladder cancers (Table 5) and
the concentrations of these can be deter-
mined in urine. Determination of VEGF has
been used to differentiate superficial (Ta)
and low grade (G1) tumors from invasive
(T1 or more) and high grade tumors (G2-
3). High urinary concentrations of VEGF
predict recurrence (Crew et al., 1997).
Several monoclonal antibodies are being
studied as tools for detection of bladder can-
cer. These identify antigens that are mostly
absent in normal bladder epithelium. Some
differentiation between various grades and
stages as well as predicition of tumor recur-
rence can be achieved (Allard et al., 1995;
Huland et al., 1987). Combinations of an-
tibodies can be used as immunocytochemi-
cal tests on voided urine (Mian et al., 1999),
and improve sensitivity and specificity when
used together with cytology.
P53 overexpression has been detected in
bladder cancer, and this is associated with
poor prognosis (Cordon-Cardo & Reuter,
1997; Sarkis et al., 1993; Tsuji et al., 1997).
However, distinct mutations of p53 occur
in bladder epithelium in smokers
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(Husgafvel-Pursiainen & Kannio, 1996),
and p53 overexpression is related to the
number of cigarettes smoked per day
(Zhang et al., 1994).
Microsatellite instability assays*
DNA-ploidy/SPF *(FCM, IA, LSCM, FISH)
Blood group-related antigens (ABO, Lewis-ag)
Growth factors (EGF*, TGFβ, FGF, VEGF*)
Cellular adhesion molecules (cadherins, integrins)
Proliferation antigens (Ki-67, PCNA)
Tumor-associated antigens* (486 P3/12, M344,
19A211, T138, DD23),
Cell cycle regulatory proteins (p53, pRb, cyclins,
p15, p16, p21)
Oncogens (c-erb-B2, ras, c-myc, c-jun, mdm2)
Components of fibrinolysis system (urokinase
type I plasmin activator)
* detection on urinary sediment or bladder wash specimens
Table 5. Potentially prognostic markers of bladder
cancer.
3. RENAL CELL CARCINOMA
3.1 Epidemiology
RCC or hypernephroma is the most com-
mon malignant tumor of the kidney ac-
counting for more than 3% of the annual
new cancer cases in Finland. It is the 7th
most common cancer among men in Fin-
land, and the 13th among women. The age-
adjusted incidence rate has nearly doubled
in the past 30 years (Dickman et al., 1999).
3.2 Risk factors
Smoking doubles the risk for RCC in both
men and women (McCredie & Stewart,
1992; McLaughlin et al., 1990). Obesity is
another reported risk, and hypertension or
medication for it have also been suspected
(Chow et al., 1996; Messerli & Grossman,
1999). Certain dietary factors may play a
role, but alcohol and coffee consumption do
not (McLaughlin & Lipworth, 2000;
Mellemgaard et al., 1996; Wolk et al.,
1996). Occupational and other exposure to
several carcinogens are suspected risk fac-
tors (Boffetta et al., 1997). Genetic predis-
position to RCC has been suggested to be
dependent on variations in metabolic path-
ways (Longuemaux et al., 1999). N-
acetyltransferase 2 participates in the me-
tabolism of drugs and carcinogens, of which
arylamines are found in tobacco smoke
(Hein et al., 1993). The so called slow-
acetylator genotype increases the risk asso-
ciated with smoking. Toxification of
nephrocarcinogenic chlorinated hydrocar-
bons proceeds by conjugation with glu-
tathione. This is mediated by glutathione
transferase, the activity of which may be
altered in RCCs to promote carcinogenesis
(Bruning & Bolt, 2000; Delbanco et al.,
2001; Grignon et al., 1994). The cyto-
chrome P450 system may similarly be in-
volved in carcinogenesis (Murray et al.,
1999).
Familial RCC accounts for less than 5%
of the cases, and most of these are associ-
ated with the von Hippel-Lindau syndrome.
This autosomal dominant disorder is caused
by errors in a tumor suppressor gene on
chromosome 3p (Latif et al., 1993). In ad-
dition to several other tumors, approxi-
mately 70% of the patients develop RCC
(Friedrich, 1999).
3.3 Histology
RCCs are adenocarcinomas arising in the
parenchymal epithelium. They are subclas-
sified into five distinct types. Conventional
(CRCC) and papillary renal cell carcino-
mas account for approximately 85-90% of
RCCs, while the chromophobe and unclas-
sified tumors account for up to 5% each.
The remainder are collecting duct tumors.
Transitional cell tumors may arise in the
transitional epithelium of the renal pel-
vis; these account for approximately 5%
of all kidney cancers. Oncocytoma is a be-
nign renal tumor (Kovacs et al., 1997).
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3.4 Symptoms and signs
The symptoms caused by RCC can be ei-
ther systemic or local. The classic triad of
local symptoms is hematuria, flank pain and
a palpable tumor mass. A rapidly develop-
ing varicocele may be caused by a tumor
invading the renal vein (left) or the inferior
vena cava. The hematuria can cause obstruc-
tion of the ureter leading to painful attacks.
Fatigue, fever and loss of weigth may occur
(Nurmi & Rintala, 2002; Nurmi et al.,
1985).
3.5 Diagnostic procedures
Renal tumors are investigated by ultra-
sonography (US), urography, computerized
tomography or magnetic resonance imag-
ing, angiography and needle biopsies. The
differentiation between renal cysts and tu-
mors is mostly possible by US. Very small
tumors can be detected by US and guided
needle biopsies can be obtained. Comput-
erized tomography is an aid in evaluating
the extent of invasion into perirenal tissues
and veins. Angiography is useful in
localising and quantitating arteries in the
planning of surgery. Bone scintigraphy and
chest radiography are used to detect bone
metastases (Hilton, 2000).
3.6 Staging and grading
Staging of RCC is performed according to
the TNM classification (Table 6) (Sobin &
Wittekind, 1997) and nuclear grading ac-
cording to Skinner and coworkers (Skinner
et al., 1971).
3.7 Treatment and prognosis
Curative treatment of RCC is usually pos-
sible only by surgical removal of the whole
tumor. This is usually achieved by radical
nephrectomy, but in selected cases nephron-
sparing surgery is an option. Response to
hormonal and cytotoxic therapies is ob-
tained in no more than 10% of the patients
(Motzer et al., 1997). Five to 20% of the
patients respond to immunotherapy based
on interferon-alpha or interleukin-2
(Malaguarnera et al., 2001; Minasian et al.,
1993; Motzer et al., 2000; Nanus, 2000;
Vogelzang et al., 1993). In approximately
one third of the patients distant metastases
are present at diagnosis (Dekernion et al.,
1978). A solitary metastasis can be removed
together with the primary tumor, and in
cases with multiple metastases removal of
the primary tumor may promote regression
of the metastases (Golimbu et al., 1986a;
Ljungberg et al., 2000; Wyczolkowski et al.,
2001).
Stage and nuclear grade are the most
important prognostic factors (Fuhrman et
al., 1982; Medeiros et al., 1988). The 5-
year survival rate in all stages is 50-60%,
but patients with metastatic disease at first
diagnosis survive only for approximately 12
months. Survival is consistently associated
with age being lowest in the highest age
groups (Dickman et al., 1999; Minasian et
al., 1993; Nurmi, 1984). A third of ini-
tially nonmetastatic tumors recur after sur-
gery, mostly incurably (Ljungberg et al.,
Tx
T0
T1
T2
T3
T3a
T3b
T3c
T4
N
M
Primary tumor can not be assessed
No evidence of primary tumor
Tumor 7 cm or less in greatest dimension,
limited to the kidney
Tumor more than 7 cm in greatest dimension,
limited to the kidney
Tumor extends into major veins, perinephric
tissues or the adrenal gland, but not beyond
Gerota fascia
Tumor infiltrates adrenal gland or perinephric
tissues, but not beyond Gerota fascia
Tumor grossly invades the renal vein(s) or
vena cava below the diaphragm
Tumor grossly extends into the vena cava
above the diaphragm
Tumor invades beyond Gerota fascia
Lymph node involvement
(N0=without, N1-2=with)
Distant metastasis (M0=without, M1=with)
Table 6. TNM classification of renal cell carcinoma
(Sobin & Wittekind, 1997).
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1999; Levy et al., 1998). Relapses can oc-
cur even decades after primary diagnosis and
the 10-year relative survival rate is approxi-
mately 45% (Dickman et al., 1999). With
the increasing use of imaging techniques
such as US and computerized tomography
the proportion of incidentally detected re-
nal tumors has been growing (Konnak &
Grossman, 1985; Smith et al., 1989). These
tumors are smaller and of lower grade and
stage. Thus, the 5-year survival rates for
patients with such tumors are significantly
higher (62-97%) than for those with symp-
tomatic ones (42-83%)(Herr, 1994; Licht
et al., 1994; Tsui et al., 2000).
3.8 Markers of RCC
RCCs are a heterogenous group of tumors
with a distinct genetic background and bi-
ology associated with the histological type
(Takahashi et al., 2001; Young et al., 2001).
The clinical outcome in the individual RCC
patient is highly variable even within a
given stage (Golimbu et al., 1986b; Kovacs
et al., 1997). Several potential RCC mark-
ers have been described, but most of these
can be studied only in surgically removed
tissues (Table 7). No specific serum mark-
ers are available. Markers that could be used
before surgery would be of value in plan-
ning of treatment and follow up.
3.8.1 Tissue markers
Several genetic aberrations have been de-
tected in RCC by restriction fragment
length polymorphism analysis, comparative
genomic hybridization, cDNA microarray
screening, in situ hybridization and
microsatellite analysis. A frequently in-
volved region is located on chromosome 3p
(Cohen et al., 1979), which also comprises
the von Hippel Lindau tumor suppressor
gene (Latif et al., 1993). Genetic losses of
3p occur commonly together with other
alterations (Velickovic et al., 2001;
Yamakawa et al., 1991). Some of these are
associated with tumor histology (Velickovic
et al., 2001), grade, stage (Morita et al.,
1991; Wada et al., 1998) or recurrence
(Moch et al., 1996; Thrash-Bingham et al.,
1995). Multiple genes are up- or down regu-
lated in RCC, and a distinction between
histologic subtypes and clinical outcome is
possible based on the expression profiles
(Takahashi et al., 2001; Young et al., 2001).
P53 mutations are fairly infrequent occur-
ring in 2-33% of RCCs (Gelb et al., 1997;
Ljungberg et al., 2001; Reiter et al., 1993;
Vasavada et al., 1998). However, p53 ex-
pression has been found to have a prognos-
tic significance  (Girgin et al., 2001) in some
papillary and chromophobe tumors, but not
in CRCCs (Gelb et al., 1997; Kamel et al.,
1994; Ljungberg et al., 2001). DNA-ploidy
has been studied as a prognostic indicator
in RCC, but its value is limited (Ljungberg
et al., 1996; Shalev et al., 2001; Tannapfel
et al., 1996). Vimentin expression can be
detected in some RCCs (Beham et al., 1992;
Dierick et al., 1991), and it may give addi-
VEGF
IL-10
CA-125
TATI
NSE
TNFβ
Ferritin
CRP
Basic FGF
Erythropoietin
Detected in
Serum Tissue
Ki-67
PCNA
AgNOR
P53
Growth factors (basic FGF)
Adhesion molecules (CD44, cadherins, catenins)
Cyclins (A)
Vimentin
Matrix metalloproteinases (2 and 9)
Tissue inhibitors of MMPs (1 and 2)
Table 7. Potential markers of RCC.
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tional prognostic information especially
when analyzed together with tumor grade
(Nativ et al., 1997; Sabo et al., 1997). Mark-
ers of cell proliferation such as nucleolar
organizer regions analysis (AgNOR), Ki-67
index and proliferating cell nuclear antigen
(PCNA) expression are promising as prog-
nostic markers (de Riese et al., 1993;
Delahunt et al., 1995; Hofmockel et al.,
1995; Tannapfel et al., 1996).
3.8.2 Serum markers
Of the many serum markers studied some
are of potential prognostic value; neuron
specific enolase (NSE), VEGF, interleukin-
10, CA-125, and tumor-associated trypsin
inhibitor (TATI) (Yaman et al., 1996;
Wittke et al., 1999; Grankvist et al., 1997;
Jacobsen et al., 2000; Paju et al., 2001).
Some of the general glycoprotein cancer
markers are detected in serum of RCC pa-
tients. CA 125 in serum is an independent
prognostic marker and CA 15-3 may also
be of some value; both markers are associ-
ated with tumor stage and grade (Grankvist
et al., 1997).
Anemia or polycythaemia may be en-
countered in RCC, suggesting involvement
of the erythropoietin processes. Elevated
serum concentrations of erythropoietin have
been described but although this is
prognostically significant the sensitivity of
this marker is too low for clinical use
(Ljungberg et al., 1992). Ferritin appears to
be produced by certain RCCs and can in
some cases be used for monitoring of the
disease (Essen et al., 1991; Kirkali et al.,
1995; Özen et al., 1995). Acute phase reac-
tants such as C-reactive protein (CRP) and
inflammatory markers such as erythrocyte
sedimentation rate may also be useful
(Ljungberg et al., 2000; Nurmi et al., 1985).
Several other general serum analytes such
as calcium, lactate dehydrogenase and he-
moglobin in combination with clinical fea-
tures and other markers have been used in
prognostic models (Motzer et al., 1999).
However, none of these are specific for can-
cer in general and even less for renal cancer.
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The aims of the study were:
1. To study whether peripheral blood cells express hCGß and how the potential expres-
sion is regulated. Expression of hCGß mRNA in blood cells would limit the utility of
hCGß mRNA as an indicator of tumor cells in circulation (I).
2. To study whether hCGß mRNA expressing cells can be detected in the cells of voided
urine from bladder cancer patients (II).
3. To compare detection of hCGß mRNA in urinary cells with serum and urinary con-
centrations of hCGß and stage and grade of the disease, and with immunohistochemical
detection of hCGß in tumor tissue (III).
4. To study whether the preoperative serum concentrations of hCGß are of prognostic
significance in patients with RCC (IV).
Aims of the study
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1. SUBJECTS AND SAMPLES (I-IV)
All studies were approved by the ethics
committees of Helsinki University Central
Hospital (HUCS) and the Finnish Red Cross
(FRC), Helsinki, Finland, and the Univer-
sity Hospital in Umeå, Sweden. Patients as
well as controls were recruited after in-
formed consent.
Whole blood buffy coats from healthy
blood donors were obtained from the Blood
Service of the FRC (I). Samples of venous
peripheral blood (I) (Tables 8 and 9) con-
trol sera (III, IV) as well as urine (II, III)
(Table 10) were collected from healthy labo-
ratory personnel from HUCS. Placental tis-
sue (I, II, III) was obtained after normal
delivery from the Department of Obstet-
rics and Gynecology, HUCS. Urine and se-
rum specimens of bladder cancer patients
and control patients (II, III) were obtained
from the Departments of Urology and Sur-
gery, HUCS. All cases studied for this the-
sis were TCCs. TCC tissue specimens as well
as samples of benign bladder tissue were
obtained from the Department of Pathol-
ogy, HUCS (Table 10). Staging of the tu-
mors was performed according to the TNM
classification of bladder cancer (UICC,
1978) and grading according to the WHO
classification of bladder tumors (Mostofi
FK, 1973) (II). In study III the more recent
consensus classification of urothelial neo-
plasms was also used (WHO/ISUP 1998).
The histological diagnosis was based on
samples obtained within two weeks of urine
sampling. Cytology of voided urine was
classified according to Papanicolaou (Papa-
nicolaou & Marshall, 1945). Sera of patients
with renal cell carcinoma (IV) were obtained
from the serum bank of the Department of
Urology and Andrology, University Hos-
pital of Umeå (Table 10). Staging of RCC
was performed according to the 1997 TNM
classification (Sobin & Wittekind, 1997),
nuclear grading according to Skinner and
coworkers (Skinner et al., 1971), and DNA-
ploidy according to Ljungberg and cowork-
ers (Ljungberg et al., 1996).
2. PREPARATIONS AND CULTUR-
ES OF CELLS (I-III)
Blood samples from five apparently healthy
nonpregnant females and six males (Table
8) were drawn into 3 ml Vacutainer EDTA
tubes (Becton Dickinson, Rutherford, NJ)
(I). Erythrocytes in peripheral blood were
hemolysed by incubating blood with 1.5 vol
of diethylpyrocarbonate-treated water for 5
min. Mononuclear cells were isolated by
Ficoll-Paque centrifugation according to the
manufacturer’s instructions (Pharmacia,
Uppsala, Sweden) and total RNA was iso-
lated (Chomczynski & Sacchi, 1987).
Urine samples (II, III) were stored at 4°
C for a maximum of six h before process-
Material and methods
Leukocyte extracts
Mononuclear cells
B-cells
T-cells
Granulocytes
Monocytes
Mononuclear cells 1
Lymphocytes 2
Peripheral blood (11) 3
Buffy coats
Buffy coats
Buffy coats
Buffy coats
Table 8. Peripheral blood cell preparations (I).
1 from peripheral venous blood of a healthy male; 2 from buffy coats;
3 five females and six males of healthy laboratory personnel.
All buffy coats were obtained from the Blood Service of the FRC.
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ing. The urinary cells were collected by cen-
trifugation and washed once with phosphate
buffered saline (PBS, 50 mM sodium phos-
phate, 150 mM NaCl, pH 7.4; HyClone
Europe Ltd, Cramlington, UK). Total RNA
was then isolated from the cell pellet.
Peripheral blood lymphocytes from
whole blood buffy coats were purified on a
Ficoll-Paque gradient (I). 1 x 106 cells/ml
were cultured in 15 ml Dulbecco’s Modi-
fied Eagle’s Medium (DMEM) (HyClone)
supplemented with 5% fetal calf serum
(FCS, Biological Industries, Kibbutz Beit
Haemek, Israel), 100 IU/l penicillin, 100
mg/l streptomycin and 2 mM L-glutamine
(GibcoBRL, Paisley, Scotland). The cells
were stimulated with phytohemagglutinin
(PHA) 10 mg/ml, concanavalin A (Con A)
2,5 mg/ml, pokeweed mitogen (PWM) at
a final dilution of 1:100, and prolactin at
different concentrations (14, 28, 70, 100,
and 140 ng/ml) (all from Sigma Chemical
Co., St. Louis, MO). Control cultures were
performed without mitogens.
Two-way mixed lymphocyte cultures
(MLC, I) were performed in 25 cm2 tissue
culture flasks with 5 x 105 lymphocytes/ml.
The cultures were incubated at 37° C in a
humified atmosphere of 8% CO
2
 in air. The
cell number and the proliferative response
to each stimulus was measured by count-
ing the proportion of lymphoblasts in the
culture by microscopy.
All cell lines (Table 9) were obtained from
the American Type Culture Collection
(ATCC) and cultured according to instruc-
tions in RPMI 1640 medium (HyClone
Europe Ltd, Cramlington, UK) supple-
mented with 10% FCS (Flow Laboratories,
UK), 2 mM glutamine (GibcoBRL), 100
IU/l penicillin, 100 mg/l streptomycin
(HyClone) and 2.5 mg/l amphotericin B
(GibcoBRL).
3. LEUKOCYTE EXTRACTS (I)
Eight ml of peripheral blood was taken in a
Vacutainer Cell Preparation Tube (Becton
Dickinson, Franklin Lakes, NJ) and mono-
nuclear cells were isolated according to the
manufacturer’s instructions (Table 8). Lym-
phocytes from whole blood buffy coats were
purified by Ficoll-Paque centrifugation. The
cells were washed twice with PBS and 108
cells were lysed in 100 µl of RIPA buffer
containing 10 mM Tris-HCl, 150 mM
NaCl, 1% sodium deoxycholate, 1% Tri-
ton X-100, 0.1% sodium dodecyl sulpahte,
1 mmol/l phenylmethanesulfonyl fluoride,
1 mM sodium vanadate, 10 mg/ml aproti-
nin (Sigma). The cell lysate was centrifuged
for 15 min at 10 000 x g and the superna-
tant was stored at -20° C until analyzed.
4. SEPARATION OF MONONUCLE-
AR CELLS, GRANULOCYTES,
MONOCYTES, B- AND T-CELLS (I)
Mononuclear cells and granulocytes were
isolated from buffy coats by density gradi-
ent centrifugation. Four ml of blood was
mixed with 6 ml of PBS, layered over 10
ml Histopaque 1077 (Sigma) and spun at
600 x g for 30 min. The mononuclear cell
layer was isolated and washed twice in PBS.
Granulocytes were separated by a triple dis-
continuous gradient (Bhat et al., 1993) by
layering 2 ml each of Histopaque 1119 at
the bottom, Histopaque 1107 (two parts
Histopaque 1119 and one part Histopaque
1083) in the middle and Histopaque 1077
on top. Two ml blood was diluted with 4
Table 9. Cultured peripheral blood lymphocytes and
cell lines.All cell lines were obtained from the ATCC
and buffy coats from the FRC.
Lymphocytes
HL-60
Jurkat
K-562
U-937
JAR
UM-UC-3
TCC-SUP
Buffy coats
Acute promyelocytic leukemia
Acute T-cell leukemia
Chronic myelogenous leukemia
Histiocytic lymphoma
Choriocarcinoma
TCC cell lines
TCC cell lines
I
I
I
I
I
I
II
II
Cell type/ line Description Used in
Material and Methods
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ml PBS and layered on top of the gradient.
The tubes were centrifuged for 30 min at
600 x g. The granulocyte cell layer was then
aspirated and washed twice with PBS. Re-
maining erythrocytes were hemolysed by
incubating the cell pellet with 4 ml dis-
tilled water for 10 s, after which 1 ml 5 x
PBS was added. The granulocytes were col-
lected by centrifugation, lysed in 4 M
guanidinium-thiocyanate buffer containing
0.1 M ß-mercaptoethanol and stored at
-20° C.
Magnetic cell sorting (MACS) was used
to separate monocytes, B- and T-cells. Cells
from the mononuclear cell layer (7,6 x 107)
were resuspended at a concentration of 107
cells per 80 µl buffer (PBS, 2 mM EDTA,
0,5% BSA), and incubated with mouse
monoclonal antibodies conjugated to mag-
netic microbeads (Miltenyi Biotec, Sunny-
vale, CA) to human CD3, CD14 or CD19
(20 µl per 107 cells). CD3 antibodies were
used for separation of T-lymphocytes, CD14
for monocytes and CD19 for B-lympho-
cytes. The labelled cells were washed twice
in the buffer and immediately processed
with a VarioMACS using an RS+ column
(Miltenyi Biotec). The column was pre-
washed with the same buffer. Positive se-
lection was done according to the manu-
facturer’s instruction. Cells from the posi-
tive fraction were eluted and washed in the
buffer. The purity of the monocyte and B-
cell fractions was determined on the basis
of morphology and expression of MHC II
antigens (Schröder et al., 1982).
5. ISOLATION OF RNA (I-III)
RNA was isolated from cells pelleted by
centrifugation of urine (II, III) as well as
from mononuclear blood cells and leuko-
cyte subsets (monocytes, B- and T-lympho-
cytes, granulocytes) and cultured cells (I)
according to Chomczynski and Sacchi
(Chomczynski & Sacchi, 1987) with Heavy
Phase Lock Gel tubes (5 Prime->3 Prime,
Inc., Boulder, CO, USA).
6. REMOVAL OF GENOMIC DNA (I-
III)
To diminish the content of genomic DNA
in the RNA preparations each sample was
subjected to DNase-treatment before RT-
PCR. Ten µg of total RNA was incubated
at 37° C for 30 min in a 50-µl reaction
mixture consisting of 1 x DNase buffer (40
mM Tris-HCl, pH 7.9, 10 mM NaCl, 6 mM
MgCl
2
, 10 mM CaCl
2
), 33 U of RNasin
(Promega, Madison, WI) and 2 U of RQ1
urinary calculi
BPH
impotence
epididymitis
inflammatory pseudotumor
chronic pyelonephritis
cystitis
hematuria
cervical carcinoma
renal carcinoma
   n
45
66
177
14
84
26
1
96
6
4
5
6
56
72
26
14
68
84
14
15
8
3
1
1
1
1
1
1
1
1
1
1
II
III
IV
III
IV
III
I, II, III
III
III
III
III
III
II
III
III
III
II
III
II
III
II, III
II
III
II, III
II
II
II, III
II, III
II, III
II, III
II
II, III
II, III
Used in
Table 10. Samples of patients and controls. The
number of patients is given in parentheses when
different from the number of samples used.
Serum samples
TCC patients (68)
TCC patients (63)
RCC patients
Control patients with benign diseases
Healthy controls
Healthy controls
Tissue samples; source
Placental tissue; normal delivery
TCC tissue; TCC patients (66)
Benign bladder
Patients with hematuria
 dysuria
  pollacisuria
 recurrent lower UTI
Urine samples
Urine
TCC patients (68)
TCC patients (63)
Healthy controls
Control patients with benign diseases
Urinary cells
TCC patients (68)
TCC patients (63)
Healthy controls
Healthy controls
Patients with acute appendicitis
Patient with urinary calculi
Patients with prostate carcinoma 3
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RNase-free DNase (Promega, Madison,
WI). The DNase was denatured for 10 min
at 55° C. RNA was precipitated with 140
µl ethanol and 5µl 2 M sodium acetate and
dissolved in diethylpyrocarbonate-treated
water.
7. OLIGONUCLEOTIDE PRIMERS
Oligonucleotide primers used for RT-PCR
of hCGß mRNA were chosen from exon 2
of the hCGß5 gene and the antisense prim-
ers from exon 3 (Figure 1).
8. RT-PCR AND GEL ELECTROPHO-
RESIS (I-III)
For RT, 1 µg of total RNA and 1 pmol of
the outer antisense primer were denatured
for 10 min at 70° C in a 12-µl volume of
diethylpyrocarbonate-treated water. The
denatured RNA was incubated in a 20-µl
reaction mixture (Lintula & Stenman, 1997)
with 200 U SuperscriptTM reverse tran-
scriptase (Gibco BRL) at 42° C for 50 min.
The RT enzyme was denaturated for 15 min
at 70° C. Contamination of RNA samples
was excluded by subjecting each sample to
the RT reaction without RT before PCR.
In the PCR, 5 µl of the cDNA mixture
was amplified in a 50-µl reaction volume
in 1x PCR buffer as previously described
(Lintula & Stenman, 1997) initially at 95°
C for 5 min, 35 cycles at 95° C for 1 min,
50° C for 1 min. One µl of the first PCR
product was further amplified with the
nested primers in a 50-µl reaction volume
for 35 cycles with an annealing tempera-
ture of 56° C but otherwise the same con-
ditions as in the first PCR.  Fifteen µl of
the product was electrophoresed on a 1.5%
agarose gel and visualized by ethidium bro-
mide staining. RNA isolated from placen-
tal tissue was used as a positive control for
hCGß and water as a negative control in all
experiments. The detection limit of the RT-
PCR was estimated by mixing the cultured
cancer cells with PBS or urine from a healthy
male to dilutions of 102-106 cells per liter
PBS or urine and with blood to give dilu-
tions up to 1 tumor cell per 107 peripheral
blood leukocytes.
9. RESTRICTION ENZYME ANALY-
SIS AND SEQUENCING OF THE
PCR PRODUCTS (I-III)
The homology between the genes for LHß
and hCGß is 94% (Talmadge et al., 1984b).
There are three mismatches between the
nucleotide sequences of the outer antisense
primer used in reverse transcription and the
B 1 3
4 2
292 bp
401 bp1+2
3+4
LHβ mRNAE3E1 E2
Figure 1. Schematic representation of the locations of the primers used for hCGβ  (a). The
primers are specific to the sequence of hCGβ mRNA, but they are also able to amplify LHβ
mRNA (b). Primer 1 is homologous to both hCGβ- and LHβ mRNA, and the dashed primers (2,
3, and 4) contain mismatches with respect to LHβ mRNA. E; exon.
Primer Sequence Nucleotides
 1 Outer sense CTG TTG CTG CTG CTG AG     50-66
 2 Outer antisense GCC TTT GAG GAA GAG GAG 436-453
 3 Nested sense ACC CTG GCT GTG GAG AAG G 128-146
 4 Nested antisense TCA TCA CAG GTC AAG GGG TG 401-420
hCGβ mRNA
A
404 bp
292 bp
1+2
3+4
1 3
4
E2 E3
2
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mRNA sequence of LHß. However, all mis-
matches are located in the 5'-end of the
primer, and amplification of LHß cDNA
occurs with these primers (Figure 1). The
identity of the PCR products produced by
the nested primers was therefore confirmed
by Hae III restriction enzyme digestion and
sequencing of the product. The 292 bp PCR
product of hCGß, but not that of LHß
mRNA, has a restriction site for Hae III
producing fragments of 108 and 184 bp,
respectively. Sequencing of the PCR prod-
ucts was performed using the nested sense
primer with the ABI PrismTM Dye Termi-
nator Cycle Sequencing Core Kit With
AmpliTaq DNA Polymerase (Perkin Elmer,
Foster City, CA).
10. DETERMINATION OF hCG,
hCGß, hCGßcf, LH AND LHß (I-IV)
Serum (II-IV), urine (II, III) and cell cul-
ture medium (I, II) were stored at -20° C
before assay of the proteins. HCG (II, III)
and hCGß (II-IV) in serum and urine, and
hCGßcf in urine (II, III) were determined
by ultra sensitive time-resolved immuno-
fluorometric assays (IFMA) (Alfthan et al.,
1992a). Cell culture media were collected
at days 3, 5 and 7 of culture and concen-
trated 14-60-fold with Centricon-3 concen-
trators (Amicon, Beverly, MA). HCG and
hCGß as well as LH and LHß in culture
media and leukocyte extracts (I) were deter-
mined by IFMA. The detection limit of the
hCG assay was 0.5 IU/l (WHO 3rd IS, 75/
537), 0.5 pmol/l for hCGß, and 0.44 pmol/
l for hCGßcf (WHO 1st IRP, 75/551). To
correct the results in urine for varying urine
concentrations the results were divided by
the concentration of urinary creatinine (II,
III). The LHß assay (LHspec, Delfia, Wallac)
detects LH, LHß, and a fragment of LHß
whereas the LH assay detects only intact LH.
The detection limit of the LH assay was 0.12
IU/l and that of the LHß assay was 0.05 IU/
l. The assays were calibrated against the 2nd
WHO IS coded 80/552.
11. IMMUNOHISTOCHEMISTRY(III)
HCGß immunoreactivity was analyzed us-
ing two monoclonal antibodies (MAbs) to
hCGß; clones 9C11 (Alfthan et al., 1988)
and 6G5 (Louhimo et al., 2001). MAb 9C11
is specific for hCGß, whereas MAb 6G5 also
reacts with intact hCG (Louhimo et al.,
2001). Immunoperoxidase staining was
performed with the Vectastain Elite ABC
Kit (Vector Laboratories Inc., Burlingame,
CA, USA). Four-µm thick, freshly cut sec-
tions of formalin-fixed, paraffin-embedded
tissue specimens were deparaffinized in xy-
lene and rehydrated by sequential incuba-
tion in graded ethanol/water solutions. The
deparaffinized tissue sections were pre-
treated with 0.5% trypsin (DIFCO labora-
tories, Detroit, MI, USA) for 30 min at 37
°C, and washed with PBS. To quench en-
dogenous peroxidase activity, the sections
were treated with 0.3% hydrogen peroxide
in methanol for 30 min at room tempera-
ture and then blocked with normal rabbit
serum (dilution 1:67) for 15 min to reduce
non-specific binding. The primary antibod-
ies diluted 1:10 000 in PBS containing
0.5% BSA (Sigma) and 0.1% sodium azide
(Merck, Darmstadt, Germany) were added
to the sections and incubated overnight at
room temperature. After rinsing, biotiny-
lated anti-mouse immunoglobulin was
added (1:200) for 30 min to the sections
followed by peroxidase labelled ABC re-
agent for 30 min. The peroxidase reaction
was developed for 15 min with 3-amino-9-
ethyl-carbazole in acetate buffer, pH 5, con-
taining 0.03% hydrogen peroxide. The sec-
tions were rinsed with water, counterstained
with haematoxylin for 35 s and rinsed with
water for 10 min. Paraffin sections of pla-
cental tissue were used as positive controls.
As a negative control a placental section was
stained by replacing the primary antibody
with normal rabbit or mouse serum. Posi-
tive staining was graded 0-3 according to
the estimated percentage of positive cells
(negative <5%; +5-25%; ++ 25-50%;
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+++50-100%). Two persons (S. N. and K.
H.) evaluated the staining independently.
12. STATISTICAL METHODS (I-IV)
Student’s paired t-test, the chi-squared test
for trend, Fisher’s exact test for correlation,
Kruskal-Wallis test and the Mann-
Whitney U test as well as receiver operat-
ing characteristic (ROC) curve analysis
were used in statistical analyses. Survival
curves were plotted using the Kaplan-
Meier method, and comparison of survival
rates was performed with the log-rank test.
The independence of hCGß as a predictor
of survival was analysed by multivariate
analysis using the Cox proportional haz-
ard model.
Material and Methods
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1. EXPRESSION OF hCGß- AND LHß
mRNA IN PERIPHERAL BLOOD
CELLS (I)
1.1 Expression of hCGß- and LHß
mRNA in peripheral blood cells and
cell lines
LHß mRNA was detected by RT-PCR in
the nucleated cells isolated from blood from
nonpregnant females and healthy males and
also in the isolated B- and T-cell fractions,
monocytes and granulocytes. HCGß mRNA
was not detected in any of these cell frac-
tions (Table 11). LH, LHß, hCG or hCGß
protein were not detected by IFMA in ex-
tracts from PBL or whole blood buffy coats.
The Jurkat and K562 cell lines expressed
mRNA for both LHß and hCGß (Table 12).
1.2 LH- and LHß expression in cultur-
ed lymphocytes
The effect of mitogens on the expression of
mRNA and protein was studied in lympho-
cyte cultures. LHß mRNA expression was
detected by RT-PCR in lymphocytes cul-
tured with and without mitogens (Table
12). PRL induced maximal mitogenic
stimulation and LH-production at a con-
centration of 100 ng/ml (Figure 2). The LH
concentrations were similar when measured
by the assays detecting only LH or both LH
and LHß indicating that the immunoreac-
tivity consisted of intact LH. The other
mitogens did not induce significant produc-
tion of LH protein, and in control cultures
without mitogen no LH immunoreactivity
was detected.
1.3 Expression of hCG protein and
hCGß mRNA and protein in cultured
lymphocytes
Culture of lymphocytes alone or with all
mitogens except PRL induced hCGß
mRNA expression (Table 12). The PCR
products were identified with Hae III,
which digests the cDNA of hCGß but not
that of LHß. However, a weak expression
of hCGß may be obscured by an excess of
LHß mRNA, potentially explaining why
no hCGß mRNA was detected in cultured
lymphocytes stimulated with PRL. No hCG
protein was detected by IFMA in the con-
trol cultures without mitogens. PHA- and
ConA stimulated cells secreted hCGß (Fig-
ure 3), but intact hCG protein was not de-
tected in any of the cultures.
Our results show that normal blood cells
express LH and that the expression is stimu-
lated by PRL. HCGß expression is not de-
tectable in unstimulated cells but it is in-
duced by culture and certain mitogens. LHß
mRNA is expressed in all the nucleated
blood cell fractions studied, and, when
stimulated with PRL, leukocytes also pro-
duced intact LH protein at readily detect-
able levels. The protein production occurred
Results and discussion
B-cell
T-cell
Granulocyte
Monocyte
+
+
+
+
-
-
-
-
mRNA expressionCell type
Table 11. LHβ- and hCGβ mRNA detected by RT-
PCR in separated peripheral blood leukocytes without
stimulation.
LHβ hCGβ
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early (after 6 h, data not shown), i.e. before
a mitogenic response was observed. This
suggests that LH expression was directly
induced by PRL and that it did not require
a mitogenic effect. In contrast, production
of hCGß protein was induced by the mito-
gens and the concentrations in the culture
medium increased with time of stimulation.
PRL has been regarded predominantly a T-
cell mitogen (Clevenger et al., 1990;
Pellegrini et al., 1992), but other T-cell spe-
cific mitogens such as Con A and PHA did
not induce translation of the genes for the
LH-subunits. The secretion of LH-protein
was highest at a PRL-concentration of 100
ng/ml, which also induced the strongest
mitogenic response. This concentration is
similar to that in pregnant and lactating
women and 5- to 10-fold that in males and
nonpregnant females. However, the concen-
trations of LH in the culture medium are
low in comparison with those of hCG oc-
curring in blood during pregnancy. Thus
the LH produced can be expected to play a
physiological role only at a paracrine or
autocrine level.
PRL is produced by lymphocytes and it
is thought to act as a growth factor for
lymphoproliferation in a paracrine or
autocrine way by inducing expression of
genes associated with lymphocyte activation
(Sabharwal et al., 1992a). PRL-receptors
have been demonstrated in both B- and T-
cells (Pellegrini et al., 1992; Dardenne et
al., 1994; Russell et al., 1985) and both cell
types respond to PRL-stimulation (Lahat et
Table 12. LHβ- and hCGβ mRNA detected by RT-PCR in cultured lymphocytes and cell lines
PHA
ConA
PWM
PRL
MLC
No mitogen
(+)= weak positive, nd= not determined
Mitogen
   LHβ   hCGβ
       +       -
       + -
       + -
       + -
       +   -
       + -
LHβ   hCGβ
      +       +
      +       +
      +       +
      +       -
      +       +
      +      (+)
LHβ   hCGβ
   +       +
   +       +
   +       +
   +       -
   +       +
   +       +
LHβ   hCGβ
   +       +
   +       +
   +       +
   +       -
   +       +
   +       -
   -       -
   +      (+)
   -        +
  (+)      +
   -        +
nd
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HL-60
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JAR
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U937
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Days of culture
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Figure 2. The effect of PRL on the production
of LH protein by cultured lymphocytes. LH, as
well as LHβ and a fragment of LHβ in the culture
medium were determined by IFMA.
**** p<0.0001; *** p<0.001; ** p<0.01; * p>0.02
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al., 1993). Luteinizing hormone-releasing
hormone (LHRH) is also thought to par-
ticipate in lymphocyte activation (Batticane
et al., 1991; Azad et al., 1993), and expres-
sion of its gene is regulated by PRL in lym-
phocytes (Wilson et al., 1995). Expression
of the hCG/LH receptor gene has been dem-
onstrated in T-lymphocytes from pregnant
women (Lin et al., 1995). In line with these
results a mitogenic LH-like protein has been
observed in thymic extracts, suggesting that
this glycoprotein would be secreted by thy-
mocytes and act as an autocrine stimulator
of lymphoproliferation (Sabharwal et al.,
1992b).
1.4 Conclusions
Together with the earlier described expres-
sion of the LH-receptor gene in T-lympho-
cytes (Lin et al., 1995) the expression of LH
in leukocytes shown here suggests that LH
may exert an autocrine function in blood
cells, possibly as a result of an autocrine or
paracrine effect of PRL. The expression of
LHß mRNA appears to occur in all periph-
eral blood leukocytes. The concentrations
of intact LH and LHß were similar when
determined separately indicating that the
immunoreactivity detected consisted of in-
tact LH. LH protein production occurred
consistently and over a wide range of physio-
logical PRL-concentrations, which supports
the notion of a physiological role of this
hormone in lymphocytes.
The expression of hCGß was induced
by mechanisms other than those stimulat-
ing LH expression, and only the free ß sub-
unit, but not intact hCG protein, could
be reliably detected. Expression of hCGß
mRNA was detected only after culture of
PBL. This is in accordance with results
from other studies showing that cultur-
ing and certain other stimuli lead to pro-
duction of hCG protein by blood cells
(Goldstein et al., 1990; Harbour-
McMenamin et al., 1986). It has been pro-
posed that mRNA for genes transcribed
in ectopic tissues at very low levels can be
detected by RT-PCR if an excessive num-
ber of amplification rounds are used (Hu
& Chow, 2000; de Graaf et al., 1997). We
tested our RT-PCR with various numbers
of cycles (20-45) and found the optimal
result for hCGß mRNA at 35 cycles,
whereas LHß mRNA could be detected
also by 30 cycles. In addition, we showed
translation of these transcripts in leuko-
cytes, demonstrating that the mRNA ex-
pression is not only a non-functional back-
ground expression. During pregnancy, cul-
tured monocytes have been reported to se-
crete hCG, and this has been suggested to
be related to the immunotolerance associ-
ated with early pregnancy (Alexander et al.,
1998). Although LH and hCGß have no
known function in lymphocytes, the ex-
pression of LH appears to be a further ex-
ample of the involvement of pituitary hor-
mones in immune modulation. Because
hCGß mRNA expression was induced by
culture it is conceivable that disorders lead-
ing to lymphocyte activation may also in-
duce hCGß expression. This may lead to
positive results for hCGß mRNA in blood
from patients without cancer. This is a
potential limitation for the use of hCGß
0.3
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Figure 3. The effect of mitogens on hCGβ production
in cultured lymphocytes. The proteins were
determined in the culture medium by IFMA at days
3, 5, and 7 of stimulation. In control cultures no
mitogen was added. The mean concentrations and
S.D. of parallel cultures are shown.
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expression for detection of cancer cells es-
pecially in blood and possibly also in urine.
2. EXPRESSION OF hCGß IN BLAD-
DER CANCER (II, III)
2.1 Immunohistochemical expression
of hCGß (III)
We detected positive staining for hCGß
equally often in sections from noninvasive
(28%) and invasive tumors (35%), and in
histologically benign samples (25%) from
TCC patients (Table 13). There was no sta-
tistically significant association between
tumor stage (p=0.6) or grade (p=0.75) and
tissue staining for hCG antigen. Positive
staining was observed in five of 26 (19%)
cases with previous instillation therapy and
in one of the 12 patients currently receiv-
ing instillations. The results were identical
with both antibodies. Furthermore, 10 of
21 (48%) samples from control tissues from
patients with benign conditions stained
positive. Two of these samples were from
control patients with hematuria and in both
cases the epithelium was oedematous and
inflamed; squamous metaplasia was ob-
served in one case with dysuria, and in a
patient with recurrent lower urinary tract
infections (UTI). One of the positively stain-
ing samples was an inflammatory pseudo-
tumor from a patient with recurrent UTI
(Table 14). Two positive samples from pa-
tients with dysuria and pollacisuria were
judged to be histologically normal.
To our knowledge, immunohistochemi-
cal expression of hCGß in benign bladder
epithelium has not been reported before, but
mRNA expression has been observed in
normal and malignant bladder epithelium
(Lazar et al., 1995) and benign transitional
cells in culture secrete hCGß into the cul-
ture medium (Iles et al., 1990b). Five of the
ten positively staining control tissues
showed signs of inflammation or squamous
metaplasia of the epithelium. Thus, it is
possible that inflammation and hyperpla-
sia may induce hCGß expression in benign
transitional epithelium. Grade and stage of
bladder cancer have been found to correlate
with immunohistochemical staining of
hCGß in most (Bacchi et al., 1993; Campo
et al., 1989; Dirnhofer et al., 1998b; Jenkins
et al., 1990; Martin et al., 1989; Moutzouris
et al., 1993; Oliver et al., 1988; Özkardes et
al., 1991), but not all earlier studies (Smith
et al., 1994). We detected immunohis-
tochemical expression of hCGß antigen in
30% of the TCC specimens but equally of-
ten in benign samples from TCC patients
(25%) and in samples from patients with
benign bladder diseases. The results were
identical with both antibodies, one of which
is specific for hCGß (Alfthan et al., 1988)
whereas the other one also reacts with in-
tact hCG. Therefore the staining most likely
originates from hCGß expression.
Expression of hCGß has been associated
with malignant transformation, lack of dif-
ferentiation of nontrophoblastic cells (Bellet
et al., 1997) and aggressive disease (Bacchi
et al., 1993; Marcillac et al., 1993; Martin
et al., 1989; Moutzouris et al., 1993). Fur-
thermore, the growth of bladder cancer cell
Table 13.  Immunohistochemical expression of
hCGβ-antigen in various stages and grades as
well as nonmalignant samples from TCC-patients.
Tis
Ta
T1
T2
T3
T4
Not available
Histologically benign
tissue*
8
46
12
4
3
1
2
20
1
14
5
0
1
1
1
5
12
30
42
0
33
100
50
25
hCGβ-positive %nStage
1
2
3
22
31
23
5
11
7
23
35
30
n= number of patients
* Samples of histologically benign bladder epithelium from patients
with cystoscopically verified TCC.
Grade
All 76 23 30
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lines in vitro is stimulated by hCGß, and it
has been proposed that hCGß acts as a
paracrine or autocrine growth factor in epi-
thelial bladder tumors (Dirnhofer et al.,
1998b; Gillott et al., 1996). The stimulat-
ing action of hCGß in bladder cancer cell
lines has been associated with an anti-
apoptotic effect interfering with normal cell
turn over (Butler et al., 2000). While these
findings suggest a role of hCGß in tumor
progression, the frequently observed expres-
sion of hCGß in benign bladder tissue ap-
pears to need another explanation. Interest-
ingly, tissue expression of hCGß has also
been observed in some other non-malignant
epithelial tissues (Iles et al., 1990b; Louhimo
et al., 2001). Thus this phenomenon is less
cancer specific than earlier thought.
2.2 HCGß and hCG in serum of blad-
der cancer patients (II, III)
Serum hCGß was moderately elevated in 18
of 45 samples (40%) in study II, and in 19
of 66 samples (29%) in study III. The con-
centrations were not significantly associated
with tumor stage or grade in either study,
or with tissue expression of hCGß. Slightly
elevated values in relation to the age and
gender-specific reference values of hCG were
observed in 4 of 43 patients (9%) in study
II, and in 12 of 66 cases (18%) in study III.
There was no difference in the serum levels
between patients with and without instil-
lation therapies. Values exceeding the up-
per reference limit of postmenopausal
women (15.5 pmol/l) occurred in 8 patients.
The concentrations of hCG, hCGß and
hCGßcf in serum and urine of bladder can-
cer patients are summarized in table 3,
original publication III.
Earlier studies have shown that elevated
serum levels of hCGß occur in up to 50%
of  patients with metastasized bladder can-
cer (Iles et al., 1989; Dexeus et al., 1986),
but only rarely in early stage disease. We
determined hCGß by a highly sensitive as-
say and found elevated serum concentra-
tions in one third of the cases including
30% (15 of 49) of those with superficial
disease. This is probably explained by the
fact that we specifically measured hCGß
rather than “total hCGß”, i.e. hCG and
hCGß together as has been done in most
earlier studies (reviewed by Iles & Butler,
1998). The upper reference limit for hCGß
is 2.1 pmol/l while that for hCG is 2.1-
15.5 pmol/l depending on age and gen-
der. A much higher cutoff was used in the
studies of Iles et al., i. e. 25 IU/l roughly
corresponding to 75 pmol/l. The sum of
hCGß and hCG did not exceed this level
in any of the sera in this study. Marcillac
and coworkers determined hCGß in serum
with a specific and sensitive technique.
With a cutoff of 100 ng/l (4.5 pmol/l) they
found elevated values in 18 of 38 patients
(47%) with TCC (Marcillac et al., 1992)
most of which had advanced disease
(Marcillac et al., 1993). These results sug-
gest that specific determination of hCGß
provides better diagnostic accuracy than
measurement of “total hCGß”. However,
we observed elevated serum levels also of
the intact hCG heterodimer in 18% of the
cases. Although the levels were only mod-
erately elevated, they were higher than in
any case in our control material. This sug-
gests that some tumors produce intact
hCG, i.e. both α and ß subunits. This is
supported by the finding of mRNA for
both subunits in some TCC tumors (Lazar
et al., 1995). Furthermore, Iles and co-
workers showed that the urinary concen-
trations of hCGα in patients with hCGß-
positive TCCs are higher than in controls
Dysuria
Hematuria
Pollacisuria
Recurrent lower UTI
All
4
6
5
6
21
3
2
2
3
10
75
33
40
50
48
Table 14.  Immunohistochemical expression of hCGβ-
antigen in bladder epithelium of patients with benign
conditions.
hCGβ-positive %nDiagnosis
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and patients with hCGß-negative TCCs
(Iles et al., 1990)
2.3 HCGß, hCG and hCGßcf in urine
of bladder cancer patients (II, III)
Elevated levels of hCGß in urine were ob-
served in only 5 of 55 cases (9%) in study
II, and in 6 of 72 (8%) cases in study III. In
10 urine samples the creatinine concentra-
tion was below 4 mmol/l and in seven of
these hCGß concentration was below de-
tection limit. The median concentrations
were higher in patients with invasive than
with noninvasive tumors (p=0.03) and in
cases with suspicious or malignant urinary
cytology (Papa IV-V) (p=0.027). A slightly
elevated value (4.6 pmol/l) was observed in
one of the control patients, who had a be-
nign inflammatory pseudotumor, which
also stained positive in immunohistochem-
istry (Table 14).
Urinary concentrations of hCGßcf were
elevated in 4 TCC samples (II, III); two of
which were from invasive grade 3 tumors.
The median urinary hCGßcf concentrations
were significantly higher in patients with
invasive than noninvasive tumors
(p=0.037), in cases with suspicious or ma-
lignant cytology (p=0.002), and in samples
positive for hCGß mRNA (p=0.03). Uri-
nary hCG was elevated in only one of 56
(2%) samples in study II and in two of 72
(3%) cases in study III. There was no dif-
ference in the urinary levels of hCGß and
hCGßcf between patients with and with-
out a history of instillation therapies, but
urinary hCG was significantly higher in
patients with previous or current instilla-
tion therapies (1.6 pmol/l) than in those
without instillations (0.4 pmol/l, p=0.04).
Theoretically, hCGß in urine might be
expected to best reflect local secretion of
hCGß from the tumor into urine. However,
the urine concentrations of hCGß were less
often elevated than those in serum. This
could be explained by large variations in
urinary flow rate leading to a wider refer-
ence range for hCGß in urine than in se-
rum (Alfthan, 1994) This effect is often
corrected for by dividing the value of uri-
nary proteins with creatinine. We calculated
this ratio for urinary hCGß but it did not
improve the diagnostic accuracy. Similarly,
correction for creatinine did not either im-
prove the correlation between the serum and
urine concentrations of luteinizing hormone
in a study on prepubertal children (Demir
et al., 1994). Although urinary flow rate
affects its protein concentration, division by
creatinine does not appear to be an optimal
method of correction. We used morning
urine, which usually is fairly concentrated,
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Figure 4. Urine to serum-hCGβ ratio in TCC patients
with benign histology, superficial and invasive tumors
at the time of sampling (a). Panel b shows the ratio
corrected for urinary creatinine concentration and
expressed per mmol creatinine in urine. Samples
with a urinary creatinine < 4 mmol/l were omitted.
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but in spite of this ten samples had a low
creatinine value (<4 mmol/l) and in seven
of these hCGß was not measurable.
Circulating hCG and hCGß are excreted
into urine, and this is normally the source
of hCGß urine concentrations. Therefore we
studied whether the ratio of urine to serum
hCGß would provide information on local
secretion of hCGß in the urinary bladder.
This ratio was significantly associated with
histology (Kruskal-Wallis test for benign,
noninvasive and invasive disease p<0.0001,
Figure 4) and differentiated between high
and low grade tumors (Kruskal-Wallis test
for grades 1 to 3 p<0.00001; Mann –
Whitney test for grade 1 versus grade 3
p=0.002 and grades 1 and 2 versus 3
p=0.009). In addition, the ratio correlated
with tissue expression of hCGß detected by
immunohistochemistry (p=0.019). This
suggests that hCGß is directly released from
the tumor into urine, whereas secretion from
the tumor into the large plasma volume has
a smaller impact on the concentrations in
circulation, which are affected by secretion
from various normal tissues.
In accordance with earlier results (Baltaci
et al., 1995; McLoughlin et al., 1991), the
correlation between serum levels of hCGß
and tissue expression was poor. Tissue ex-
pression did not either correlate with uri-
nary hCGß. The ß-core fragment has been
demonstrated by immunohistochemistry in
TCC of the bladder (Dirnhofer et al., 1998b)
and thus hCGßcf might be released directly
from the tumor into urine. Urinary hCGßcf
correlated with the invasiveness of the tu-
mor and positivity for hCGß mRNA in
urinary cells. However, elevated urine lev-
els were rare and hCGßcf in urine was not
useful as a marker.
2.4 HCGß mRNA in urinary cells (II,
III)
In study II, hCGß mRNA was detected in
29 of the 68 (43%) samples of urinary cells
form TCC patients and in none of the
healthy controls (n=14). There was a highly
significant association between histologi-
cally verified TCC and hCGß mRNA in
urinary cells (p=0.0014). In study III 42 of
84 (50%) urinary cell samples were posi-
tive for hCGß mRNA. The positive cases
tended to have a higher urine to serum ra-
tio of hCGß (p=0.088) and hCGßcf con-
centrations in urine than the negative ones
(p=0.03), but there was no correlation with
tumor stage or grade (Table 15), urinary
cytology, immunohistochemical hCGß ex-
pression and serum marker levels. Previous
(more than 2 months earlier) or current in-
stillation therapies did not either affect the
result; 12 of 23 (52%) cases were positive.
All healthy controls were negative, but in
four of the 23 control patients (II, III) hCGß
mRNA was present in the urinary cells.
Three of these had a UTI and one had he-
maturia of unknown origin.
HCGß mRNA in urinary cells is strongly
associated with TCC. However, this was also
detected in some patients with benign dis-
eases, i. e.  infection or hematuria. We found
that hCGß mRNA expression may be
incuced in leukocytes. Therefore hematuria
and inflammation may be expected to cause
a positive result in RT-PCR of hCGß
mRNA in urinary cells. However, although
hematuria occurred in several patients with
TCC it was not consistently associated with
Tis
Ta
T1
T2
T3
T4
Not available
8
41
13
4
2
1
15
5
18
8
2
0
1
8
62
44
62
50
0
100
53
hCGβ mRNAn %Stage
Grade
Table 15. HCGβ mRNA in urinary cells from TCC
patients according to tumor stage and grade.
1
2
3
All
21
26
22
84
7
16
10
42
33
62
45
50
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a positive RT-PCR. It is possible that in-
fections, instillation therapies, instrumen-
tation and other conditions causing cellu-
lar atypia and inflammation also induce
hCGß mRNA expression in transitional
epithelium. The more frequent expression
in patients with TCC could be explained
by increased shedding of TCC cells from
cancerous epithelium. However, half of the
patients with a histologically verified tu-
mor had a negative RT-PCR. This could be
associated with a variable recovery of tu-
mor cells in urine, or to selective expres-
sion of hCGß. Different hCGß genes are
expressed in benign and malignant bladder
epithelium. Our primers were designed ac-
cording to the sequence of the hCGß5 gene
which is expressed in TCC (Lazar et al.,
1995).
3. HCGß EXPRESSION IN SERUM
OF  RCC PATIENTS (IV)
The concentration of hCGß in serum was
elevated (>2 pmol/l) in 23% of the patients
with RCC and 20 of these (11%) had val-
ues > 4pmol/l. The median concentration
of hCGß in serum was 1.2 pmol/l (range
0.2 - 18 pmol/l), which was significantly
higher (p<0.0001) than in controls (median
0.4 pmol/l, range 0.2 - 1.3 pmol/l). The
serum concentrations of hCGß were not re-
lated to serum creatinine. There was no dif-
ference in hCGß levels between males and
females, different age groups, different RCC
types, aneuploid and diploid tumors, or
tumors with and without venous invasion.
Serum hCGß concentrations were not ei-
ther significantly correlated with tumor
stage or grade (Figure 5).
Clinical stage and grade were highly pre-
dictive of disease specific survival
(p<0.0001 each) in univariate analysis. Pa-
tients with serum hCGß concentrations
above the median value (1.2 pmol/l) had
significantly shorter survival than those
with lower levels (p=0.0029) (Figure 6A).
A difference in survival time was observed
also among patients with metastasized tu-
mors (stage IV, Figure 6B) (p=0.06). When
serum hCGß concentration was compared
as quartiles there was no difference in dis-
ease specific survival between the two low-
est quartiles or between quartiles 3 and 4
(p>0.6). In multivariate analysis using the
Cox regression model with age, gender, se-
rum hCGß, nuclear grade and stage as in-
put variables, stage, grade, and serum hCGß
concentration were independently associ-
ated with the disease specific survival (Table
16).
RCC is known for its unpredictable clini-
cal behavior and within stages and grades
the clinical course is highly variable. Recur-
rence can occur many years after apparently
successful surgery and metastases may spon-
taneously regress after removal of the pri-
mary tumor (Golimbu et al., 1986b). Sev-
eral biomolecular markers have been stud-
ied as potential markers for RCC, but to date
there is no specific clinically useful serum
marker. Of the many serum markers stud-
ied, only a few, i. e. VEGF, interleukin-10,
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Figure 5. Boxplot demonstrating preoperative
serum hCGβ concentrations in RCC patients with
various stages. The horizontal line indicates the
upper reference limit for serum hCGβ (2.1 pmol/l).
Stage
Grade
Stage
hCGβ
1.15
2.34
0.48
=0.032
<0.0001
=0.022
3.2 (1.1-9.0)
10.3 (4.8-22.3)
1.6 (1.1-2.5)
Coefficient (β) p
 
      RR
Table 16. Factors independently associated with
decreased cumulative survival of patients with RCC
(RR = Relative risk).
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CA-125, and TATI are of potential prog-
nostic value (Wittke et al., 1999; Grankvist
et al., 1997; Jacobsen et al., 2000; Paju et
al., 2001). There is little data on hCGß ex-
pression in renal tumours. Dexeus and co-
workers observed increased hCGß concen-
trations in serum of 10% of the patients,
and changes in the levels correlated with the
clinical course (Dexeus et al., 1991). We
found elevated concentrations in 23% of the
patients, and the median concentrations
were significantly higher than in controls
(p<0.0001). Patients with serum hCGß lev-
els above the median value (1.2 pmol/l) had
significantly shorter survival than those with
lower levels (p<0.0029), and in multivari-
ate analysis serum hCGß, tumour stage and
grade were independent prognostic vari-
ables. The fairly low frequency (23%) of el-
evated serum hCGß suggest that this marker
is expressed by only part of the RCCs. How-
ever, because normal levels between 1.2 and
2.1 pmol/l were associated with adverse
prognosis, it is possible that part of the
hCGß in these patients is derived from the
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Time (months)tumor. The absence of a correlation with
stage indicates that elevated levels are not
only a result of tumor burden but that hCGß
expression characterizes a subgroup of tu-
mors. The lack of significant correlation
with established prognostic variables such
as grade and stage demonstrates the inde-
pendent character of this marker.
The clinical utility of hCGß in the man-
agement of RCC is limited by the infre-
quent expression. About one fourth of the
patients had elevated levels and in half of
these the elevation was substantial. How-
ever, a prognostic value was observed even
with normal levels exceeding the median
value. Furthermore, the prognostic signifi-
cance of hCGß in serum was seen not only
in patients with metastatic disease, but also
in earlier stages (stages I-III). Thus it ap-
pears worthwhile to study whether hCGß
could be used in identifying a subgroup of
patients with increased risk of aggressive
disease and as an aid in the selection of
therapy, as well as in monitoring of the dis-
ease after primary therapy.
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Summary
Methods for detection of cancer cells in
blood and body fluids have been extensively
studied in attempts to evaluate tumor
spread. The presence of cancer cells in cir-
culation reflects the metastatic potential of
the tumor, although it is not necessarily a
sign of metastatic disease. RT-PCR is a
highly sensitive method of detecting can-
cer cells expressing a tumor- or tissue spe-
cific mRNA. With the best methods a
single tumor cell may be detected among
107 leukocytes. However, a prerequisite is
that peripheral blood cells do not express
the mRNA used as a marker of cancer cells.
Recently expression of several genes thought
to be specific for other organs has been de-
tected in blood cells, and leukocytes have
the potential of producing many peptide
hormones and receptors for these. HCG is a
glycoprotein hormone consisting of two
subunits, α and ß. It is produced at high
concentrations by placental trophoblasts to
maintain pregnancy. Isolated low level ex-
pression of hCGß commonly occurs in ma-
lignant tumors and this is associated with
agressive disease.
We studied whether hCGß mRNA could
be used as a marker of cancer cells in blood
and urine. To confirm the specificity of the
method we first studied whether hCGß
mRNA is expressed by peripheral blood
cells. HCGß mRNA expression was de-
tected by RT-PCR in cultured blood cells,
but not in isolated peripheral blood leuko-
cytes. HCGß mRNA expression occurred
in the urinary cells from half of the patients
with bladder cancer, and this was strongly
associated with histological evidence of can-
cer. However, there was no association with
stage or grade of the disease. Urine concen-
trations of hCGß were elevated in less than
10% of the cases, while the serum concen-
trations of hCGß and of intact hCG were
elevated in 30-40% and 10-20%, respec-
tively. However, the ratio of urine to serum
concentration of hCGß protein was signifi-
cantly associated with both stage and grade
of the tumor, and also with immunohis-
tochemical staining of hCGß in tumor tis-
sue.
Immunohistochemical expression of
hCGß was observed in approximately one
third of the tumors, and this was not asso-
ciated with stage and grade. We also de-
tected hCGß protein in benign transitional
epithelium in 30% of the cases. In most of
these the expression was associated with
inflammation or squamous metaplasia.
In previous studies, the serum concen-
trations of hCGß have been found to have
prognostic value in bladder cancer, ovarian
cancer, cancer of the oral cavity, orophar-
ynx and colon. The prognostic significance
of hCGß expression in bladder cancer was
not studied, but the strong correlation be-
tween urine to serum ratio of hCGß and
stage and grade of the disease suggest an
association between hCGß expression and
advanced and high grade tumors.
Because hCGß appears to be a universal
serum marker for aggressive cancers we stud-
ied the prognostic value of the preoperative
serum concentrations of hCGß in patients
with renal cell carcinoma (RCC). Serum
hCGß was elevated in 23% of the patients.
In addition to stage and grade, serum hCGß
was an independent prognostic marker, and
normal levels exceeding the median were
Kristina Hotakainen
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also of prognostic value. In preliminary stud-
ies we have found that hCGß can be detected
by immunohistochemistry in approximately
15% of conventional RCCs and this is asso-
ciated with survival.
Our results add further support to pre-
vious studies linking hCGß to a potentially
aggressive subgroup of tumors. A possible
explanation for this association is the re-
cently described anti-apoptotic effect of
hCGß, but the detailed mechanism re-
mains to be investigated.
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1. HCGß expression was detected in cultured peripheral blood lymphocytes but not in
unstimulated cells. Because hCGß mRNA expression was induced by culture, disorders
leading to lymphocyte activation may also induce hCGß expression giving positive re-
sults for hCGß mRNA in blood from patients without cancer. This is a potential limita-
tion for the use of hCGß expression for detection of cancer cells in blood and possibly also
in urine.
2. HCGß mRNA expression was detected in the urinary cells of 50% of the patients with
bladder cancer but not in healthy controls. There was no association with stage or grade of
the disease. The positive results in some benign diseases suggest that infections, instru-
mentation and other conditions causing cellular atypia and inflammation also induce hCGß
mRNA expression in transitional epithelium.
3. Immunohistochemical expression of hCGß in bladder cancer was not associated with
stage and grade of the tumor. The positivity in benign bladder tissues shows that the
phenomenon is not restricted to malignant tumors but inflammation and metaplasia may
also induce expression. While previous studies suggest a role of hCGß in tumor progres-
sion, these findings suggest that hCGß expression also is involved in growth stimulation.
4. Urinary hCGß and hCGßcf correlated with urinary cytology and the ratio of urine to
serum concentration of hCGß protein was significantly associated with both stage, grade,
and immunohistochemical staining. This suggests that hCGß is secreted into urine by
many bladder tumors and supports the previously reported association between hCGß
expression and advanced and high grade tumors.
5. Serum hCGß was elevated in 23% of the RCC patients and levels above the median
concentration were independently associated with shorter survival. The absence of a corre-
lation with stage indicates that elevated levels are not only a result of tumor burden. The
fairly small proportion of RCC patients with elevated hCGß suggests that hCGß is not
expressed by all tumors, but the expression identifies a subgroup of RCCs with unfavourable
prognosis, supporting previous studies linking hCGß to aggressive tumors.
Conclusions
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